Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meeting21-12-2021
21-12-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 850 Equity shares under ESOP21-12-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meeting21-12-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meeting16-12-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meeting15-12-2021
Gland Pharma share price gains 2% on tentative approval from USFDA for cangrelor
The scrip touched a 52-week high of Rs 4,324.65 and a 52-week low of Rs 2,050 on 13 August, 2021 and 16 December, 2020, respectively.09-12-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Product tentative approval-Cangrelor for Injection08-12-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Schedule of Investor Meetings08-12-2021
Buy Gland Pharma; target of Rs 5000: Emkay Global Financial
Emkay Global Financial is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated November 29, 2021.01-12-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meetings01-12-2021